Deafness is one of the most common congenital birth defects. Worldwide, the incidence of hearing loss in newborns is 1.86‰, and more than 60% of deafness cases are attributed to genetic factors. Hereditary deafness is classified into two categories: Syndromic…

On June 9, 2025, Xinya Gene announced that GEN6050X, its proprietary in vivo base-editing therapeutic candidate, had obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for DMD treatment. This recognition marks a landmark milestone for…